AURORA LABS LIMITED — Capital/Financing Update 2018

Mar 1, 2018

ASX ANNOUNCEMENT

2 March 2018

==> picture [595 x 99] intentionally omitted <==

ISSUE OF PLACEMENT SHARES AND UPDATE TO SECURITY PURCHASE PLAN TIMETABLE

Aurora Labs Limited (“Aurora” or “the Company”) (ASX: A3D) refers to its previous announcement on 26 February 2018 (‘Replacement – Aurora Labs launches $8 million capital raising’).

Settlement under Placement

The Company is pleased to announce that, in conjunction with Hunter Capital Advisors Pty Ltd as lead manager, it has today effected settlement of the private placement to sophisticated and professional investors announced to ASX on 26 February 2018 ( Placement ).

The Company has issued 6,250,000 fully paid ordinary shares at $0.80 each to the investors under the Placement, raising $5 million (before costs). These shares were issued pursuant to the Company’s issuing capacity under Listing Rule 7.1. Enclosed with this announcement is a cleansing notice and an Appendix 3B new issue announcement in relation to the Placement shares and shares issued upon conversion of options

Placement investors will receive an entitlement to apply for one free-attaching option (exercisable at $1.00 each within 2 years of grant) for every 2 shares subscribed under the Placement. This offer will be made by way of a prospectus to be issued by the Company in early March 2018 which will also contain the Company’s proposed security purchase plan offer of shares and free-attaching options to certain eligible shareholders ( SPP ).

The issue of securities under the SPP and the issue of free-attaching options to Placement investors is subject to approval of the Company’s shareholders at a general meeting proposed to be held in April 2018.

Updated Indicative Timetable

Set out below is the updated indicative timetable for the Placement and SPP.

Event	Target date
Record Date	5:00pm (WST) on Friday, 23 February
(date for determining shareholders’ entitlements to	2018
participate in the SPP)
Placement and SPP announced and Company’s	Monday, 26 February 2018
shares re-commence trading on the ASX
Placement shares issued	Friday, 2 March 2018
Prospectus lodged with ASIC	Wednesday, 7 March 2018
SPP documents (including Prospectus) mailed to	Friday, 9 March 2018
Eligible Shareholders
Opening date for SPP offer
Notice of general meeting mailed to shareholders	Wednesday, 14 March 2018

==> picture [594 x 70] intentionally omitted <==

Closing date for acceptance

Cl	osing date for acceptance	5:00pm (WST) on
		Wednesday, 4 April 2018
General Meeting		Friday, 13 April 2018
Issue of:		Friday, 13 April 2018
•	Free-attaching options to Placement investors
•	SPP shares and free-attaching options to SPP
	investors
•	Shortfall shares and free-attaching options to
	investors under shortfall offer

• Options to lead manager pursuant to lead manager mandate Trading of new SPP shares and all options to Monday, 16 April 2018 commence

Notes:

1. Subject to the ASX Listing Rules, the dates in the table above are indicative only and are subject to change.

2. Highlighted rows in the table above denote events which have occurred.

For further information please contact:

enquiries@auroralabs3D.com

ABOUT AURORA LABS

Aurora Labs Limited (“the Company”) (ASX:A3D), an industrial technology and innovation company that specialises in the development of 3D metal printers, powders, digital parts and their associated intellectual property.

Aurora Labs is listed on the Australian Securities Exchange (ASX:A3D).

To learn more about Aurora Labs please visit: www.auroralabs3d.com

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’ or ‘expects’. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside Aurora’s control.

Accordingly, Aurora and the directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur.

==> picture [595 x 70] intentionally omitted <==

==> picture [195 x 51] intentionally omitted <==

2 March 2018

Company Announcements Office Australian Securities Exchange

NEW ISSUE OF SECURITIES - CLEANSING NOTICE AND APPENDIX 3B

Aurora Labs Limited ( Company ) has today issued the following securities ( Securities ) to be quoted on ASX:

1. 6,250,000 ordinary fully paid shares ( Shares ) at an issue price of $0.80 per Share to raise $5 million (before costs) pursuant to a placement to sophisticated and institutional investors managed by Hunter Capital Advisors Pty Ltd; and

2. 354,500 Shares issued on the exercise of 354,500 unquoted options exercisable at $0.20 each on or before 31 December 2018 (A3DAH).

The Company gives the following cleansing notice under section 708A(5)(e) of the Corporations Act 2001(Cth) ( Corporations Act ) that:

1. The Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. As at the date of this notice, the Company has complied with;

3. 2.1 the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

4. 2.2 section 674 of the Corporations Act; and

5. As at the date of this notice, there is no information to be disclosed which is ‘excluded information’, as defined in sections 708A(7) or 708A(8) of the Corporations Act.

An Appendix 3B new issue announcement in relation to the issue of the Securities by the Company is now attached.

Yours Sincerely

AURORA LABS LIMITED

Unit 2 76 Bushland Ridge, Bibra Lake, Western Australia, 6163 Tel: +61 (0)8 94341934 PO Box 1531, Bibra Lake DC, Western Australia 6965

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Aurora Labs Limited

ABN

44 601 164 505

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of+securities issued or to be issued 2 Number of+securities issued or to be issued (if known) or maximum number which may be issued 3 Principal terms of the+securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) 4 Do the+securities rank equally in all respects from the date of allotment with an existing+class of quoted+securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or	Ordinary shares (fully paid)
	a. 354,500 ordinary shares (fully paid) issued on exercise of options b. 6,250,000 ordinary shares (fully paid) issued under a placement (Placement)
	All shares issued are fully paid ordinary shares.
	Yes.

interest payment

• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration a. $0.20 per share (shares issued on exercise of options) b. $0.80 per share 6 Purpose of the issue The funds raised by the Placement will be used (If issued as consideration for to support the acceleration of the development of the acquisition of assets, clearly Aurora’s Large Format Technology and general identify those assets) working capital requirements. Refer the announcement by the Company on 26 February 2018. 6a Is the entity an[+] eligible entity Yes. that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the[+] securities the subject of this Appendix 3B , and comply with section 6i 6b The date the security holder 29 November 2017. resolution under rule 7.1A was passed 6c Number of[+] securities issued 6,250,000 shares under the Placement. without security holder approval under rule 7.1 6d Number of[+] securities issued Not applicable. with security holder approval under rule 7.1A 6e Number of[+] securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of securities issued 354,500 (Exception 4) – options were issued prior under an exception in rule 7.2 to the Company’s admission to ASX. 6g If securities issued under rule Not applicable. 7.1A, was issue price at least 75% of 15 day VWAP as calculated

• See chapter 19 for defined terms.

Appendix 3B Page 2

01/08/2012

under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 8 Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable) 9 Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)
	Not applicable.
	LR 7.1: 2,555,365 LR 7.1A: 5,893,707
	Shares issued on exercise of options, and shares issued under the Placement were issued on Friday, 2 March 2018.
	Number	+Class
	32,961,575	Ordinary fully paid shares
	Number	+Class
	32,260,696 1,020,425 9,092,500 480,000 931,000 40,000	Ordinary Shares (restricted securities) Unquoted Options Exercisable at $0.20 Expiring 31/12/2018 (A3DAH) Restricted Unquoted Options Exercisable at $0.20 Expiring 31/12/2018 (A3DAG) Unquoted Options Exercisable at $2.23 Expiring 30/11/2019 (A3DAI) Unquoted Options Exercisable at $3.00 Expiring 31/03/2020 (A3DAI) Unquoted Options Exercisable at $1.17 Expiring 30/06/2020 (A3DAI)

477,000 Unquoted Options Exercisable at $0.79 Expiring 31/08/2020 (A3DAI) 50,000 Unquoted Options Exercisable at $0.72 Expiring 30/09/2020 (A3DAI) 100,000 Unquoted Options Exercisable at $0.95 Expiring 31/07/2020 (A3DAI) 14,700,000 Performance Shares (A3DAJ): • 7,087,500 Class B • 7,612,500 Class C

• 10 Dividend policy (in the case of a Not applicable. trust, distribution policy) on the increased capital (interests)

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval Not applicable. required? 12 Is the issue renounceable or nonNot applicable. renounceable? 13 Ratio in which the[+] securities Not applicable. will be offered 14 +Class of +securities to which the Not applicable. offer relates 15 +Record date to determine Not applicable. entitlements 16 Will holdings on different Not applicable. registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements Not applicable. in relation to fractions

• See chapter 19 for defined terms.

Appendix 3B Page 4

01/08/2012

18 Names of countries in which the entity has+security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of+security holders 25 If the issue is contingent on +security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable)	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.
	Not applicable.

30 How do[+] security holders sell Not applicable. their entitlements in full through a broker? 31 How do[+] security holders sell Not applicable. part of their entitlements through a broker and accept for the balance? 32 How do[+] security holders dispose Not applicable. of their entitlements (except by sale through a broker)? 33 +Despatch date Not applicable.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities ( tick one ) (a)[ Securities described in Part 1 ]

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders 36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

• See chapter 19 for defined terms.

Appendix 3B Page 6

01/08/2012

37 A copy of any trust deed for the additional[+] securities

Entities that have ticked box 34(b)

38 Number of securities for which Not applicable. +quotation is sought 39 Class of +securities for which Not applicable. quotation is sought 40 Do the[+] securities rank equally in Not applicable. all respects from the date of allotment with an existing[+] class of quoted[+] securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation Not applicable. now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

Number +Class 42 Number and +class of all +securities quoted on ASX Not applicable. ( including the securities in clause 38)

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

• 2 We warrant the following to ASX.

• The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

• There is no reason why those[+] securities should not be granted +quotation.

• An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

• 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: (Company Secretary)

Date: 2 March 2018

Print name: Mathew Whyte

• See chapter 19 for defined terms.

== == == == ==

Appendix 3B Page 8

01/08/2012

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

Part 1	Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated
Insertnumber of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	55,000,000
Addthe following: • Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid ordinary securities that became fully paid in that 12 month period Note: • Include only ordinary securities here – other classes of equity securities cannot be added • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items	•100,000 (shares issued 03/03/2017) •194,000 (shares issued on 29/08/2017) •167,500 (shares issued on 03/10/2017) •196,075 (shares issued on 13/11/2017) •125,000 (shares issued on 19/12/2017 on exercise of Options, LR 7.2 exception 4) •354,500 (shares issued on 02/03/2018 on exercise of Options, LR 7.2 exception 4) •2,800,000 (Shares issued under placement on 03/03/2017 ratified pursuant to LR 7.4 at EGM held on 12/6/2017) N/A
Subtractthe number of fully paid ordinary securities cancelled during that 12 month period	Nil
“A”	58,937,075

• See chapter 19 for defined terms.

Appendix 3B Page 9

01/08/2012

Step 2: Calculate 15% of “A”

Step 2: Calculate 15% of “A”	Step 2: Calculate 15% of “A”
“B”	[Note: this value cannot be changed]
Multiply“A” by 0.15	8,840,561
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used
Insertnumber of equity securities issued or agreed to be issued in that 12 month period not counting_those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 _Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items	• 35,196 (shares issued on 03/03/2018) • 6,250,000 (shares issued 02/03/2018)
“C”	6,285,196
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1
“A” x 0.15 Note: number must be same as shown in Step 2	8,840,561
Subtract“C” Note: number must be same as shown in Step 3	6,285,196
Total[“A” x 0.15] – “C”	2,555,365 [Note: this is the remaining placement capacity under rule 7.1]

placement capacity under rule 7.1
“A” x 0.15	8,840,561
Note: number must be same as shown in
Step 2
Subtract“C”	6,285,196
Note: number must be same as shown in
Step 3
Total[“A” x 0.15] – “C”	2,555,365
	[Note: this is the remaining placement
	capacity under rule 7.1]

• See chapter 19 for defined terms.

Appendix 3B Page 10

01/08/2012

Part 2

Part 2	Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated
“A” Note: number must be same as shown in Step 1 of Part 1	58,937,075
Step 2: Calculate 10% of “A”
“D”	Note: this value cannot be changed
Multiply“A” by 0.10	5,893,707
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used
Insertnumber of equity securities issued or agreed to be issued in that 12- month period under rule 7.1A Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items	Nil
“E”	Nil

• See chapter 19 for defined terms.

Appendix 3B Page 11

01/08/2012

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A
“A” x 0.10 Note: number must be same as shown in Step 2	5,893,707
Subtract“E” Note: number must be same as shown in Step 3	Nil
Total[“A” x 0.10] – “E”	5,893,707 Note: this is the remaining placement capacity under rule 7.1A

• See chapter 19 for defined terms.

Appendix 3B Page 12

01/08/2012